501014-33-1

Upstream product

• 142573-75-9 N⁴-benzoyl-1-[2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-erythro-pentofuran-3'-ulosyl]cytosine 
• 72409-30-4 N⁴-benzoyl-2'-O-(tert-butyldimethylsilyl)-5'-O-(4-monomethoxytrityl)cytidine 
• 72409-15-5 N⁴-benzoyl-5'-O-(4-monomethoxytrityl)cytidine 
• 65-46-3 CYTIDINE 
• 13089-48-0 N₄-benzoylcytidine 
• 93-97-0 benzoic acid anhydride 
• 72429-30-2 N⁴-benzoyl-2',5'-di-O-tert-butyldimethylsilylcytidine 
• 501014-32-0 N⁴-benzoyl-2'-O-(tert-butyldimethylsilyl)-3'-keto-5'-O-(4-monomethoxytrityl)cytidine 

Downstream Products

• 501014-34-2 N⁴-benzoyl-2'-O-(tert-butyldimethylsilyl)-3'-C-(trimethylsilylethynyl)cytidine 
• 180300-43-0 3'-ethynylcytidine 
• 674784-56-6 C₂₂H₃₀⁽²⁾HN₃O₆Si 

Relevant academic research and scientific papers

Synthesis of 2'-deuterio and 3'-deuterio cytidine 5'-diphosphate.

2'-2H- and 3'-2H-CDP were synthesized from 5'-MMT-3'-O-TBDMS and 2',5'-O-diTBDMS cytidine derivatives, respectively, by oxidation followed by acidic removal of 5'-protection, reduction with [NaBD(OAc)3] and finally displacement of a tosyl group by pyropho

A new laboratory scale synthesis for the anticancer drug 3′-C-ethynylcytidine

A new synthetic route for the preparation of larger quantities of the anticancer nucleoside analogue 3′-C-ethynylcytidine is described. Starting from cytidine which was orthogonally protected in three steps, the ketonucleoside analogue as the key intermediate was obtained through oxidation of the unprotected 3′-hydroxy group. Stereoselective addition of the trimethylsilyl-protected acetylide residue at the 3′-carbonyl group followed by a complete deprotection afforded 3′-C-ethynylcytidine in an overall yield of 24% in seven steps.